Feb. 6, 2003 — Ertapenem once daily was as efficacious and well tolerated for intra-abdominal infections as piperacillin/tazobactam four times daily, according to ...
For the first time since 2010, the Infectious Disease Society of America published new guidelines for treating complex abdominal infections. The revisions were prompted by “significant morbidity and ...
Credit: Shutterstock. No significant differences in clinical cure rates were observed between short-course and prolonged-course antimicrobial therapy in patients with intraabdominal infections. SAN ...
The Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), in combination with metronidazole, for patients 18 years and older who have limited or no alternative options ...
The FDA has approved aztreonam and avibactam (Emblaveo) in combination with metronidazole for adults who have limited or no alternative options for the treatment of complicated intra-abdominal ...
Feb 7 (Reuters) - AbbVie (ABBV.N), opens new tab said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections, including those caused by ...
The Food and Drug Administration (FDA) has approved Recarbrio (imipenem, cilastatin, relebactam; Merck) for the treatment of adult patients aged 18 years and older with complicated urinary tract ...
DUBLIN, Ireland and CHICAGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing an oral and IV penem antibiotic to ...
Doribax (doripenem injection), a 500-mg IV infusion for treating complicated UTIs (cUTI), including pyelonephritis, as well as intra-abdominal infections (cIAI), has received marketing clearance. In ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Merck’s three-drug combination antibiotic injection, Recarbrio, for the treatment of ...
The US Food and Drug Administration (FDA) has approved the antibacterial drug trio imipenem, cilastatin, and relebactam (Recarbrio, Merck) for complicated urinary tract infection (cUTI) and ...
Approval of this indication is based on limited clinical safety and efficacy data for Emblaveo. In REVISIT, study participants with cIAI (n=312) were randomly assigned 2:1 to receive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results